实用临床医药杂志2017，Vol.21Issue(7)：39-42,46,5.DOI:10.7619/jcmp.201707011
雷替曲塞联合奥沙利铂与FOLFOX4方案治疗中晚期原发性肝癌的疗效评价
Clinical efficacy of raltitrexed combined with oxaliplatin and FOLFOX 4 protocol in treatment of patients with middle and advanced primary liver cancer
摘要
Abstract
Objective To explore the clinical efficacy and drug-toxic reactions of raltitrexed combined with oxaliplatin (RALOX protocol) and 5-fluorouracil + calciumfolinate + oxaliplatin (FOLFOX 4 protocol) in the treatment of patients with middle and advanced primary liver cancer (PLC).Methods A total of 72 patients with PLC were selected and randomly divided into RALOX group (n =34) and FOLFOX 4 group (n =38).The objective response rate (RR) was evaluated every 6 weeks after chemotherapy,while objective remission rate (OR),disease-control rate (DCR),median survival rate (mOS),median progression-free survival (mPFS),1-year survival rate (SR) as well as toxic and adverse reactions were observed.Results In RALOX group,31 patients were evaluable,with OR,DCR,mOS,mPFS,and 1-year SR being 19.4％,51.6％,7.2 months,3.4 months,and 22.6％,respectively.In FOLFOX 4 group,29 patients were evaluable,with OR,DCR,mOS,mPFS,and 1-year SR being 13.8％,48.3％,6.9 months,3.3 months and 20.7％,respectively.RALOX group was significantly lower than FOLFOX 4 group in the incidence rates of gastrointestinal reactions,liver toxicity,cardiac toxicity,peripheral nervous toxicity and hand-foot syndrome,but there were no significant differences in the incidence rates of renal toxicity and myelosuppression between two groups.Conclusion RALOX is safe and effective in the treatment of patients with middle and advanced PLC,and is superior to FOLFOX 4 protocol in clinical efficacy with mild adverse reactions.关键词
原发性肝癌/奥沙利铂/雷替曲塞/FOLFOX 4方案/化疗Key words
primary liver cancer/oxaliplatin/raltitrexed/FOLFOX 4 protocol/chemotherapy分类
医药卫生引用本文复制引用
沈永奇,黄军,陈超庭,斯韬,王志祥,谢华东,孔祥应,刘金娥,韩朝稳..雷替曲塞联合奥沙利铂与FOLFOX4方案治疗中晚期原发性肝癌的疗效评价[J].实用临床医药杂志,2017,21(7):39-42,46,5.基金项目
广西壮族自治区卫计委科研项目(Z2014408) （Z2014408）
广西壮族自治区柳州市科技攻关项目(2014J030424) （2014J030424）
